Compare BridgeBio Pharma Inc (BBIO) vs Waste Management, Inc. (WM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Waste Management, Inc. — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Waste Management, Inc. trades at $226.76 (market cap $90.58B). The key difference: Waste Management, Inc. is far larger — about 5.5× BridgeBio Pharma Inc's market cap, and Waste Management, Inc. pays a 1.56% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | WM | |
|---|---|---|
Market Cap | $16.61B | $90.58B |
Sector | Health | Industrials |
52-Week High | $90.17 | $246.51 |
52-Week Low | $47.29 | $196.77 |
Enterprise Value | $18.16B | $113.37B |
Dividend Yield | — | 1.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
WM trades at $227.68, down 0.58% on the day, with a bullish technical signal supported by moving averages and oversold RSI levels. The company reported Q2 2026 EPS of $2.02, beating estimates, with revenue growth to $25.2 billion in 2025. Valuation ratios are elevated, with a P/E of 59.96 and P/S of 16.1, reflecting premium pricing. Recent news highlights margin gains and institutional activity, including Bank of America reducing holdings by 6.1% in Q1 2026 (Defense World, 2026-08-01).
The outlook remains positive with a consensus price target of $263.43, implying 15.7% upside, driven by pricing discipline and technology investments. Risks include high debt levels, with a debt-to-asset ratio of 53.62% in 2024, and softer volume trends. Earnings momentum from recent beats supports growth, but margin pressures and economic sensitivity could limit gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Waste Management, Inc.
Waste Management ranks as the largest integrated provider of traditional solid waste services in the United States, operating approximately 260 active landfills and about 340 transfer stations. The company serves residential, commercial, and industrial end markets and is also a leading recycler in North America.
Read more on WM →
